The Farmabrasilis Infectious Disease Proposal
|
|
- Ashlyn Coleen Smith
- 5 years ago
- Views:
Transcription
1 The Farmabrasilis Infectious Disease Proposal A new, powerful, affordable immunomodulator and a strategy for large-scale deployment Goals and strategy The final goal of our organization is to contribute to the fight against TB, malaria and other infectious diseases, particularly in developing countries, where the problem is compounded by the spread of HIV-AIDS. Focusing on this goal, and as a StopTB partner, we introduce our proposal, based on the following three points: - A new product - A new therapeutic approach - A scheme to allow its universal use, in particular by disadvantaged populations The new product is the immunomodulator P-MAPA outlined below, which has been under development for the last 17 years by Farmabrasilis. It has already passed preclinical and pilot trials. The new therapeutic approach is the reestablishment of immunocompetence of patients with infectious diseases, including those co-infected with HIV, by adjuvant immunotherapy with P-MAPA. A key aspect of this proposal is the scheme for universal use. P-MAPA is an affordable immunomodulator, obtained by a classical fungal fermentation process. No high technology needs to be involved. Farmabrasilis has developed a large-scale, low-cost production technology of P-MAPA, and is in a position to transfer the know-how to its partners, even in countries with no tradition of pharmaceutical manufacture. Furthermore, our product licensing policy includes the possibility of royalty-exempt transference of technology in the case of neglected diseases and economically disadvantaged populations.br
2 Product description and project rationale Emerging and reemerging diseases caused by intracellular pathogens, such as tuberculosis and malaria, are major causes of morbidity and mortality globally. The appearance of drug-resistant strains of several pathogens underlies the need for the development of new medicines, including those capable of boosting host immune response. This is important in infections by intracellular pathogens since conventional vaccines and antibody-based therapies are often partially or totally ineffective against such pathogens. A candidate to play this role is the immunomodulator P-MAPA. P-MAPA: the substance The immunomodulator P-MAPA is a proteinaceous aggregate of ammonium and magnesium phospholinoleate palmitoleate anhydride derived from A. oryzae. P-MAPA was originally intended for cancer treatment, and has effectively demonstrated anti-tumor activity in several mouse models. 1 Furthermore, recent advances in the understanding of its mechanism of action expanded its potential field of therapeutic application. Evidence is accumulating that the compound modulates the production of Interferon-gamma and interleukin-10 (background, details and references about this mechanism are provided below). Because these are key substances in the body defenses against TB, malaria and other infectious diseases caused by intracellular pathogens, it is reasonable to hypothesize that P-MAPA may be applicable to them. Immunocompetence and infectious diseases Experiments in animal models and pilot clinical trials in humans have repeatedly suggested that P-MAPA is able to reestablish the immunocompetence when the immune system is impaired by neoplasic or infectious diseases. Although an interaction between HIV and infectious diseases, such as TB and malaria, has not yet been definitely established, there is substantial evidence suggesting that these pathogens may interact and modify the pathogenesis of each disease. An important consequence for public health is that an efficient treatment of these concurrent infections may have the additional effect of retarding the spread and progression of HIV infection. Thus, the reasoning underlying our proposal for an immune-based therapy of infectious diseases is that an ineffective cell-mediated immune response is a characteristic feature of many diseases caused by a variety of intracellular pathogens, including M. tuberculosis..br
3 Ineffective immunity in these infections is often associated with depressed T-helper type 1 (Th1) cytokine response, and reduced production of Interferon-gamma. Interleukin-10 (IL-10) is thought to be a central mediator of the depressed Interferongamma response in diseases from intracellular pathogens. 2 Likewise, during the course of HIV-1 infection, secretion of Th1 cytokines, such as Interleukin-2 (IL-2), and antiviral Interferon (Interferon-gamma), is generally decreased, whereas production of T helper type 2 (Th2) cytokines, IL-4 and IL-10 is increased. 3 Because of these similarities in the mechanisms of infection of TB and HIV, exogenously produced Interferon-gamma has been used to attempt to reestablish host immunocompetence. Restrictions of exogenous Interferon-gamma therapy Exogenous Interferon-gamma therapy in patients co-infected with HIV and tuberculosis receiving TB medication improves clinical outcome and enhances the host defense mechanism. 4 The same has been reported when Interferon-gamma is used as adjuvant in the treatment of tuberculosis patients having a resistance to standard chemotherapy. 5 In malaria, there is also strong evidence of a correlation between the use of exogenous Interferon-gamma and immunoprotection in experimental models against blood-stage forms of the parasite. 6 Although immune-based therapy, mainly by administration of exogenous Interferongamma, is a promising path to treating these infectious diseases, it is still plagued by serious problems and dilemmas, such as occasionally severe side effects, and a very high cost, making it nearly impracticable for large-scale use in developing countries. Proposed therapeutic approach In view of this, an innovative approach for treating these diseases would be to administer agents that enhance production of physiological amounts of Interferongamma through an immunoregulatory mechanism, and modulate IL-10 production. The immunomodulator P-MAPA seems to have this ability, possibly even under concomitant infection by HIV. A reestablishment of immunocompetence by the increase of Interferon-gamma levels and the decrease of IL-10 levels, resulting in host protection and high survival rates of animals, has been consistently associated with P- MAPA in animal model studies for infectious diseases and cancer. 1 Preclinical results from rodent and non-human primate studies have demonstrated substantial amplification of immune responses in general. *.br
4 In summary, there is evidence that P-MAPA induces proliferation of T lymphocytes, modulates cytokine production, mainly Interferon-gamma and Interleukin-2, and increases NK cell activity and nitric oxide (NO) release by macrophages 1, resulting in therapeutic effects in a remarkably wide range of pathologies - as expected from an immunomodulator - including infectious diseases caused by intracellular pathogens and cancer, both in animal models and in humans. Specific experiments for intracellular pathogens Tuberculosis: P-MAPA is currently under investigation for its in vivo anti- Mycobacterium tuberculosis activity using murine models (C57BL/6 mice). Experimental data has shown that the compound significantly reduces the bacterial load in the lungs of treated animals. Further studies are in progress with appropriate animal models to evaluate its use in conjunction with current antimicrobials. 7 Listeriosis: In an animal model for the study of infection by intracellular pathogens, using Listeria monocytogenes-infected mice (Balb/C mice), experimental data has shown that previous treatment with P-MAPA stimulated myelopoiesis in a dosedependent manner, and enhanced Interleukin-2 and Interferon-gamma production of post-challenged animals. Moreover, treatment with P-MAPA significantly reduced death of mice lethally infected with Listeria monocytogenes. The experiment has shown that P-MAPA can modulate the growth and differentiation of bone marrow granulocytemacrophage progenitor cells (CFU-GM) and cytokine production, resulting in a remarkably increased resistance to bacterial infection. 1 Malaria: In malaria animal model studies (C57BL/6 mice), experimental data has shown that treatment with different doses of P-MAPA in P. chabaudi infected mice and P. yoelii infected mice, in the blood stage of the disease, significantly reduced parasite proliferation. 8 Safety There is abundant evidence from pre-clinical and preliminary clinical trials that P- MAPA is a safe drug. It has not shown significant toxic effects on mice, rats, monkeys, nor in pilot trials in humans. Furthermore, it has not shown any teratogenic effects either in vitro or in vivo studies -- which may allow its use for the treatment of TB and malaria during pregnancy. * Because the action of P-MAPA is on the immune system rather than against the pathogens themselves, it is unlikely that it will cause the emergence of resistant varieties of tuberculosis and malaria parasites. In pre-clinical studies, no effect on virus replication was observed when P- MAPA was added in vitro to infected HIV-I-CEM cells. * Therefore, on the basis of currently available data, the compound is not expected to increase the replication of HIV in vivo..br
5 In addition, in pilot clinical trials for cancer and HIV, no interference with other medication has been observed. It is reasonable to expect that this will also hold true for medication for HIV, TB and malaria. Vision The combined results of the above studies constitute strong evidence that: (a) P-MAPA is able to reestablish the immunocompetence when the immune system is impaired by neoplasic and infectious diseases, and (b) it does so through an immunomodulatory mechanism. If this is borne out by Phase II and Phase III clinical trials, this medicament is expected to have an extensive impact on the treatment of infectious diseases. If P-MAPA succeeds in reverting or minimizing the ineffective cellular immune response often associated with infections such as TB and malaria even in HIV-infected patients, its use in conjunction with other therapies may represent a significant advance in the treatment of these concurrent infections. An important consequence for public health is that an efficient treatment of these concurrent infections may have the effect of retarding the spread and progression of HIV infection. Of course it could also be deployed to combat these infections in non-hiv- infected patients, increasing the effectiveness of therapies currently in use. It may represent a new and powerful weapon in the therapeutic arsenal against MDR-TB and XDR-TB. Thus P-MAPA, in combination with current therapies, might be an important contribution to the treatment of infectious diseases caused by intracellular pathogens, such as TB. Together with the Farmabrasilis policy of cost-free licensing for disadvantaged populations, we hope that this approach will benefit large numbers of people in geographic regions with a high prevalence of HIV. Invitation Farmabrasilis welcomes new partners to help advance this project. We will be glad to discuss different partnership formats to pursue common goals. Visit us at Stand 22 of the StopTB Forum in Rio de Janeiro, or write to: alliances@farmabrasilis.org.br
6 Assets Farmabrasilis has four valuable assets to share with partners. Product. P-MAPA is one of the few medicines with immunotherapeutic action in the pipeline today that, according to evidence, could help face such major challenges as TB or malaria. Time savings. P-MAPA has 17 years of development behind it, and is ready for clinical trials. Cost savings. Achieving the current stage of development of P-MAPA usually requires massive amounts of funds. Expertise. The Farmabrasilis team has developed the product and its production process, and can also provide assistance in planning and executing clinical trials. Terms of partnership Farmabrasilis is open to partnerships with individuals, groups or institutions committed to improving public health in different parts of the world. We expect our partners to agree to the Farmabrasilis basic policies. In particular, our licensing policy includes the possibility of royalty-exempt transference of technology in the case of neglected diseases and disadvantaged populations. This means that, in such cases, partners cannot sell the medicines or the technologies associated to them, nor gain any other direct or indirect benefits. Farmabrasilis - an outline Farmabrasilis is a non-profit research network congregating Brazilian, Chilean, American, and European scientists. Since 1987 it has been developing innovative and efficient medicaments for infectious diseases and cancer, with special emphasis on neglected diseases and disadvantaged populations..br
7 Selected references 1 JUSTO GZ, DURAN N, QUEIROZ MLS. Myelopoietic response in tumour-bearing mice by an aggregated polymer isolated from Aspergillus oryzae. Eur. J. Pharmacol. 2000, 388: ; MELO A, JUSTO GZ, QUEIROZ MLS. Stimulation of myelopoiesis in Listeria monocytogenes-infected mice by an aggregated polymer isolated from Aspergillus oryzae. Human. Exp. Toxicol. 2001, 20: 38-45; JUSTO GZ, DURAN N, QUEIROZ MLS. Natural killer cell activity, lymphocyte proliferation and cytokines profile in tumour-bearing mice treated with P-MAPA, a magnesium aggregated polymer from Aspergillus orizae. Immunopharm. Immunotoxicol 2003, 25: N.BROMBERG JUSTO, G.Z. JUSTO, SEABRA A.B., DURAN N. - " Macrophage nitric oxide (NO) stimulation by an immunomodulator: P-MAPA " - Nitric Oxide 14 (2.006) - A 37 - P GONG J-H, ZHANG M, MODLIN RL, LINDSEY PS, IYER D, LIN Y, BARNESI PF. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infection and Immunity 1996, 64:3; KEDZIERSKA K, CROWE SM. Cytokines and HIV-1: interactions and clinical implications. Antiviral Chemistry & Chemotherapy 2001, 12: YOLA A, SOLOGUB T, NECHAEV V, IVANOV A. Immune-based therapy using gamma interferon ingaron in the treatment of HIV/AIDS patients with active pulmonary tuberculosis (PTB) not previously highly active antiretroviral therapy (HAART) Retrovirology 2006; 3 (Suppl 1):S38. 5 SUAREZ-MENDEZ R, GARCÍA- GARCÍA I, FERNÁNDEZ-OLIVEIRA N, QUINTANA MV, MILANÉS- VIRELLES MT, CARBONELL D, MACHADO-MOLÍNA D, VALENZUELA-SILVA CM, LÓPES-SAURA PA. Adjuvant interferom gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infectious Diseases 2004, 4:44. 6 SHEAR HL, SRINIVASAN R, NOLAN T, NG C. Role of IFN-.gamma. in lethal and nonlethal malaria in susceptible and resistant murine hosts. J. Immunol. 1989, 143: ; HUGOSSON E, MONTGOMERY SM, PREMJI Z, TROYE-BLOMBERG M, BJÖRKMAN A. IL-10 levels and clearance of P. falciparum higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunology, 2004, 26 (3): 111-7; LUTY AJ, LELL B, SCHMIDT-OTT R, LEHMAN LG, LUCKNER D, GREVE B, MATOUSEK P, HERBICH K, SCHIMID D, MIGOT-NABIAS F, DELORON P, NUSSENZWEIG RS, KREMSNER PG. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 1999, 179(4): Submitted. 8 DURAN M, MARCATO P, COSTA FTM, DURAN N, TASIC L. Structure and Antimalarial Activity of Immunomodulator P-MAPA. 2 nd World Conference on Magic Bullets - Ehrlich II, Nürnberg, Germany Absctract DURAN M, COSTA FTM, BROCCHI M., LOPES S, TASIC L, NUNES I, DURAN N. An immunomodulator against malaria infection. XXXII Congress of the Brazilian Society for Immunology NUNES I. Building a new model for pharmaceuticals: P-MAPA, a novel immunomodulator against virus, bacterial, and protozoan infections. International Conference on Drug Design and Discovery for Developing Countries, Trieste, Italy, 2008, Abstract I-8-P85. * Preclinical and clinical studies: P-MAPA-Product Monograph (
Effects of P-MAPA Immunomodulator on Toll-like Receptors and Angiogenesis: Potential Therapeutic Strategies For Non-Muscle Invasive Bladder Cancer
UNIVERSITY OF CAMPINAS (UNICAMP) INSTITUTE OF BIOLOGY DEPARTAMENT OF STRUCTURAL AND FUNCTIONAL BIOLOGY Effects of P-MAPA Immunomodulator on Toll-like Receptors and Angiogenesis: Potential Therapeutic Strategies
More informationProf. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology
By Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology Lecture objectives: At the end of the lecture you should be able to: Enumerate features that characterize acquired immune response
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationSuraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable
United States House of Representatives Committee on Appropriations Subcommittee on State and Foreign Operations and Related Programs Fiscal Year 2020 Written Testimony Suraj Madoori, Treatment Action Group,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adaptive immune response biologic response modifiers and, 735 737 S-Adenosylmethionine (SAMe) for hepatitis, 825 826 Albinterferon for hepatitis,
More informationCHAPTER I INTRODUCTION. for both infectious diseases and malignancies. Immunity is known as the innate
CHAPTER I INTRODUCTION 1.1. Background of Study The immune system s function is to provide defense of the human body for both infectious diseases and malignancies. Immunity is known as the innate immunity
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationUNRAVELING THE MYSTERY BEHIND HIV/AIDS
PRESS RELEASE 3 MAR 2010 UNRAVELING THE MYSTERY BEHIND HIV/AIDS New findings by Nobel Laureate shed light on the elusive AIDS virus and may lead to effective HIV vaccine development 1. Professor Francoise
More informationNational Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018
National Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018 The NHMRC has publically released results (embargo lifted on 11 October
More informationMalaria parasite vaccine development Strategies & Targets
Malaria parasite vaccine development Strategies & Targets Tulane University Ahmed Aly Most malaria disease deaths are among children and pregnant women A child or a pregnant woman dies of malaria nearly
More informationFluid movement in capillaries. Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system
Capillary exchange Fluid movement in capillaries Not all fluid is reclaimed at the venous end of the capillaries; that is the job of the lymphatic system Lymphatic vessels Lymphatic capillaries permeate
More informationBiological Therapies for Cancer: Questions and Answers
Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationPathogens and the immune system
Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu Keck Hall 224 / 232-lab Lecture 8 BIOE 301-Bioengineering and World Health Review of lecture 7 Science Science is the human activity
More informationWriting Effective Grant Proposals
WritingEffectiveGrantProposals SUPPLEMENTALHANDOUT EXERCISES (toaccompanypowerpointslidepresentation) PamelaDerish ScientificPublicationsManager DepartmentofSurgery,UCSF tel415.885 7686 Pamela.Derish@ucsfmedctr.org
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationAnimal Models to Understand Immunity
Animal Models to Understand Immunity Hussein El Saghire hesaghir@sckcen.be Innate Adaptive immunity Immunity MAPK and NF-kB TLR pathways receptors Fast Slow Non-specific Specific NOD-like receptors T-cell
More informationNIAID GL OBAL HEAL TH RESEAR CH PL AN FOR HIV/AIDS, MAL ARIA, AND TUBER CUL OSIS
NIAID GL OBAL HEAL TH RESEAR CH PL AN FOR HIV/AIDS, MAL ARIA, AND TUBER CUL OSIS M a y 7, 2 0 0 1 NA TIONAL INSTITUTE OF ALLER GY AND INFECTIOUS DISEASES NA TIONAL INSTITUTES OF HEAL TH U.S. DEP AR TMENT
More informationAnti-Inflammatory cytokines and haematological indices in hiv seropositive adults with uncomplicated plasmodium falciparum malaria.
own Anti-Inflammatory cytokines and haematological indices in hiv seropositive adults with uncomplicated plasmodium falciparum malaria. Tatfeng Mirabeau 1, Agbonlahor Dennis 2 and Olalekan Adeshola 3.
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationContents The Cytokine System The Discovery of the Brain Immunomodulators
Contents 1 The Cytokine System... 1 1.1 Inducible Character of Cytokine Formation and Reception... 1 1.2 Locality of Cytokine Action... 2 1.3 Superfluity of Cytokine System... 2 1.4 Interrelationship and
More informationC. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.
Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen
More informationInternational Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard
International Partnership for Microbicides Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard Dr. Zeda Rosenberg February 20, 2007 The Face of HIV Globally Increasingly
More informationCell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)
Chapter 16 CELL MEDIATED IMMUNITY Cell Mediated Immunity Also known as Cellular Immunity or CMI The effector phase T cells Specificity for immune recognition reactions TH provide cytokines CTLs do the
More informationTHE IMMUNE SYSTEM Chapter 40 (Miller & Levine)
THE IMMUNE SYSTEM Chapter 40 (Miller & Levine) 40 1 Infectious Disease A. How Diseases Are Spread 1. Vectors animals that carry disease-causing organisms from person to person (ticks, mosquitos, other
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationChapter 24 The Immune System
Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationPATHOGENS AND DEFENCE AGAINST INFECTIOUS DISEASE. By: Stephanie, Emily, Cem, and Julie
PATHOGENS AND DEFENCE AGAINST INFECTIOUS DISEASE By: Stephanie, Emily, Cem, and Julie Pathogen Pathogen: an organism or virus that causes a disease. Examples: bacteria, fungi, protozoa, virus Disease Cause
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationMICROBIOLOGY - An Overview
MICROBIOLOGY - An Overview Hieucam Phan, MD Pediatrics St. Luke s Hospital San Francisco, CA Microbiology 6/01 1 Introduction Major Achievements of Medical Sciences in the 20th Century Microbiology DNA
More informationمحاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases
محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases Immunity to infection depends on a combination of innate mechanisms (phagocytosis, complement, etc.) and antigen
More informationPress Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT)
Press Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT) Results from innovative tuberculosis vaccine trial show potential for new BCG revaccination strategies
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationSection Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B
Section Director: Cliff Bellone, Ph.D. Office: Doisy Hall - R 405 Phone: 577-8449 E-Mail: bellonec@slu.edu Lecturers: James Swierkosz, Ph.D. Office: Medical School Rm. 412 Phone: 577-8430 E-Mail: swierkoszje@slu.edu
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationUnderstanding vaccine development
Understanding vaccine development Firdausi Qadri Director, Centre for Vaccine Sciences International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) Outline of this talk 1. Understanding disease
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationUnited Nations General Assembly June 8, 2011
Remarks by Dr. Mathilde Krim United Nations General Assembly June 8, 2011 I am Mathilde Krim, the Founding Chairman of amfar, The Foundation for AIDS Research. This is a not-for-profit foundation based
More informationA Hopeful Beginning for Malaria Vaccines
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-global-medicine/a-hopeful-beginning-for-malariavaccines/4043/
More informationChapter 1. Full file at
Chapter 1 1. Which is the best definition of immunity? Answer: B A. The state of having been exposed to a pathogen repeatedly B. The state of being resistant to reinfection with a pathogen C. When an individual
More informationDeveloping a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India
University of Chicago Center in Delhi Developing a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India Organizers United States: Evan Lyon, MD Assistant Professor of Medicine, Department
More informationChapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
More informationEXPERIMENTAL MODELS OF CEREBRAL MALARIA
EXPERIMENTAL MODELS OF HASTINGS OZWARA, PhD MALARIA PROGRAMME INSTITUTE OF PRIMATE RESEARCH P. O BOX 24481, KAREN - 00502 NAIROBI TEL 254 20 882571/4 FAX 254 20 882546 E-MAIL: OZWARA@IPR.OR.KE INTRODUCTION
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationChapter 40 Section 2 The Immune System
Chapter 40 Section 2 The Immune System Science Standard 10a What is the role of the skin in providing nonspecific defenses against infection? What is the function of the immune system? The immune system
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationFIFTH WORKSHOP CLINICAL AND IMMUNOLOGICAL ASPECTS OF VACCINOLOGY PROCEEDINGS. 8 th -12 th October 2018 Haunersche Kinderklinik - Munich, Germany
FIFTH WORKSHOP CLINICAL AND IMMUNOLOGICAL ASPECTS OF VACCINOLOGY 8 th -12 th October 2018 Haunersche Kinderklinik - Munich, Germany PROCEEDINGS Organization and Graphic project by: INTRODUCTION GLYCOVAX
More informationThe WHO END-TB Strategy
ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationThe Western Pacific Region faces significant
COMBATING COMMUNICABLE DISEASES A medical technician draws blood for HIV screening in Manila. AFP elimination of mother-to-child transmission of HIV and congenital syphilis was piloted in Malaysia and
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationHIV depletes T-helper17, we simply stimulate it. By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I.
HIV depletes T-helper17, we simply stimulate it By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I. Natural Healthcare for HIV infected HIV depletes T-helper17, we simply stimulate it Dr.Pichaet Wiriyachitra
More informationPART A. True/False. Indicate in the space whether each of the following statements are true or false.
MCB 55 Plagues and Pandemics Midterm I Practice questions Read each question carefully. All the questions can be answered briefly, in the space allotted. PART A. True/False. Indicate in the space whether
More informationMEETING OF INTERESTED PARTIES
WORLD HEALTH ORGANIZATION MEETING OF INTERESTED PARTIES GENEVA, 3 TO 7 NOVEMBER 2003 Timetable and annotated agenda Please note that the timetable is indicative and that the timing of discussions may vary
More informationThe contribution of research with monkeys to progress in medical science
Transplantation Reduction animal testing Chronic diseases Infectious diseases The contribution of research with monkeys to progress in medical science Contents Contents Introduction.... 3 Transplantation...
More informationHelminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza
Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels
More informationIntegrative Healthcare Symposium 2010 Using Transfer Factor to Strengthen Cell-Mediated Immunity
Using Transfer Factor to Strengthen Cell-Mediated Immunity Presented by 1 Introduction 1949 NYU immunologist Dr. H. Sherwood Lawrence transferred immunity to tuberculosis (TB) Injected filtered leukocyte
More informationCampbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System Multiple-Choice Questions
Campbell's Biology: Concepts and Connections, 7e (Reece et al.) Chapter 24 The Immune System 24.1 Multiple-Choice Questions 1) The body's innate defenses against infection include A) several nonspecific
More informationRestoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.
Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which
More informationBasis of Immunology and
Basis of Immunology and Immunophysiopathology of Infectious Diseases Jointly organized by Institut Pasteur in Ho Chi Minh City and Institut Pasteur with kind support from ANRS & Université Pierre et Marie
More informationGap identification as a critical step to enable integrated clinical trial simulation platforms
Gap identification as a critical step to enable integrated clinical trial simulation platforms Application to TB Eline van Maanen Joost de Jongh Peter Vis September 26, 2013 LEIDEN EXPERTS ON ADVANCED
More informationDefense mechanism against pathogens
Defense mechanism against pathogens Immune System What is immune system? Cells and organs within an animal s body that contribute to immune defenses against pathogens ( ) Bacteria -Major entry points ;open
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationImmunology lecture: 14. Cytokines: Main source: Fibroblast, but actually it can be produced by other types of cells
Immunology lecture: 14 Cytokines: 1)Interferons"IFN" : 2 types Type 1 : IFN-Alpha : Main source: Macrophages IFN-Beta: Main source: Fibroblast, but actually it can be produced by other types of cells **There
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationPage 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
More information16 Innate Immunity: M I C R O B I O L O G Y. Nonspecific Defenses of the Host. a n i n t r o d u c t i o n
ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 16 Innate Immunity: Nonspecific Defenses of the Host PowerPoint Lecture Slide Presentation prepared by Christine L.
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationDEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION
DEVELOPMENT The European Union confronts HIV/AIDS, malaria and tuberculosis A comprehensive strategy for the new millennium EUROPEAN COMMISSION DE 121 FEB 2004 A global challenge Every minute, 11 people
More informationChapter 38- Immune System
Chapter 38- Immune System First Line of Defense: Barriers Nonspecific defenses, such as the skin and mucous membranes, are barriers to potential pathogens. In addition to being a physical barrier to pathogens,
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationThe EU strategy in Horizon2020 to fight poverty related diseases
Meeting on EDCTP2 French Ministry of Education, Science and Innovation, Paris 30 June 2017 The EU strategy in Horizon2020 to fight poverty related diseases Line Matthiessen Acting Director Health Directorate
More informationThe Wistar Institute is an international leader in biomedical
A LEADER IN RESEARCH The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology and infectious disease research. The Institute works actively to
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationRoche to provide HIV diagnostic solutions to Global Fund. Framework agreement with Global Fund strengthens access to HIV diagnostics
Media Release June 18, 2015 Roche to provide HIV diagnostic solutions to Global Fund Framework agreement with Global Fund strengthens access to HIV diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced
More informationIVI STRATEGY ARTICULATION. October 12, 2015
IVI STRATEGY ARTICULATION October 12, 2015 Overall messages for today Our Vision and Mission are as relevant today as they have ever been We need to focus on the diseases and activities where we can have
More informationResolution adopted by the General Assembly. [without reference to a Main Committee (A/62/L.39 and Add.1)]
United Nations General Assembly Distr.: General 7 March 2008 Sixty-second session Agenda item 47 Resolution adopted by the General Assembly [without reference to a Main Committee (A/62/L.39 and Add.1)]
More informationUpdate on Tuberculosis Vaccines
March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the
More informationPartnerships in TB Vaccine Research & Development. James E. Connolly President & CEO Aeras Global TB Vaccine Foundation
Partnerships in TB Vaccine Research & Development James E. Connolly President & CEO Aeras Global TB Vaccine Foundation Aeras Mission & GLOBAL the TB VACCINE PDP FOUNDATION Model Develop new, more effective
More informationLecture 11. Immunology and disease: parasite antigenic diversity
Lecture 11 Immunology and disease: parasite antigenic diversity RNAi interference video and tutorial (you are responsible for this material, so check it out.) http://www.pbs.org/wgbh/nova/sciencenow/3210/02.html
More informationBasis and Clinical Applications of Interferon
Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance
More informationNATURAL KILLER T CELLS EBOOK
08 April, 2018 NATURAL KILLER T CELLS EBOOK Document Filetype: PDF 90.41 KB 0 NATURAL KILLER T CELLS EBOOK Natural killer T cells (NK T cells) are a type of lymphocyte, or white blood cell. Natural killer
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationHuman Biology: Immunology and Public Health. level 6 (3 SCQF credit points)
Human Biology: Immunology and Public Health SCQF: level 6 (3 SCQF credit points) Unit code: H4LB 76 Unit outline The general aim of this Unit is to develop skills of scientific inquiry, investigation and
More informationGlobal health and vaccination: TB & beyond. Dr Mary Moran Executive Director
Global health and vaccination: TB & beyond Dr Mary Moran Executive Director mmoran@policycures.org Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where
More informationStudy Guide 23, 24 & 47
Study Guide 23, 24 & 47 STUDY GUIDE SECTION 23-3 Bacteria and Humans Name Period Date 1. One bacterial disease that is transmitted by contaminated drinking water is a. Lyme disease b. gonorrhea c. tuberculosis
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationmalaria epidemics FD90C2A80F37419F A1B6C58 Malaria Epidemics 1 / 6
Malaria Epidemics 1 / 6 2 / 6 3 / 6 Malaria Epidemics WHO/HTM/RBM/2003.49 Part II Prevention and control of Tutor's Guide World Health Organization HIV/AIDS, Tuberculosis and Malaria Prevention and control
More informationRole of iron in invasive fungal infections
Role of iron in invasive fungal infections Günter Weiss Department of Internal Medicine Clinical Immunology and Infectious Diseases Medical University of Innsbruck, Austria Iron at the host-pathogen-interface
More information